![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 33, 22985-22992, August 13, 1999
From the Department of Biochemistry, University of Alberta,
Edmonton, Alberta T6G 2H7, Canada
We examined regulation of the
Na+/H+ exchanger isoform 1 by
phosphorylation in the rat myocardium. We utilized cell extracts from
adult rat hearts, adult rat extracts fractionated by fast performance
liquid chromatography, and extracts from cultured neonatal cardiac
myocytes. The carboxyl-terminal 178 amino acids of the
Na+/H+ exchanger were expressed in
Escherichia coli fused with glutathione S-transferase. The purified protein was used as a substrate
for in vitro phosphorylation and in-gel kinase assays.
Unfractionated extracts from neonatal myocytes or adult hearts
phosphorylated the COOH-terminal domain of the antiporter. Western blot
analysis revealed that mitogen-activated protein (MAP) kinase (44 and
42 kDa) and p90rsk (90 kDa) were present in specific fractions
of cardiac extracts that phosphorylated the COOH-terminal protein.
In-gel kinase assays confirmed that protein kinases of approximately 44 and 90 kDa could phosphorylate this domain. MAP kinase and
p90rsk-dependent phosphorylation of the antiporter
could be demonstrated by immunoprecipitation of these kinases from
extracts of neonatal cardiac myocytes. PD98059, a mitogen-activated
protein kinase kinase inhibitor, decreased MAP kinase and
p90rsk phosphorylation of the antiporter and abolished serum
and endothelin 1-stimulated increases in steady-state pHi.
These results confirm the presence of MAP kinase-dependent
phosphorylation in the regulation of the Na+/H+
exchanger in the rat myocardium and suggest an important role for
p90rsk phosphorylation in regulation of the protein by
endothelin-mediated stimulation of the antiporter.
The Na+/H+ exchanger isoform-1
(NHE1)1 is a ubiquitously
expressed integral membrane protein (1) with a molecular mass of about
100 kDa (2). It localizes to the plasma membrane, where it functions in
the maintenance of cytosolic pH (pHi) and intracellular volume
(3). Six isoforms (NHE1-NHE6) exist, which vary in molecular weight
and in sensitivity to the inhibitor amiloride (1, 4).
The exchanger functions by extruding one proton in exchange for one
sodium ion when pHi is too acidic (5). An amino-terminal
membrane domain mediates transport, and a cytosolic, hydrophilic
carboxyl-terminal domain of approximately 300 amino acids in length (1,
3) regulates activity. The Na+/H+ exchanger is
the protein responsible for removing most acid equivalents in the
myocardium, particularly in cases of acute acid load (6). It is
suggested that Na+/H+ exchange is important in
modulating the cardiac response to reperfusion after ischemia (7). The
increases in intracellular sodium from the activity of the exchanger
result in calcium overload by the Na+/Ca2+
exchanger and subsequently lead to increased damage to the myocardium (7). These facts underlie the importance of understanding the regulatory mechanisms functioning to control
Na+/H+ exchange.
Studies have shown that phosphorylation of the
Na+/H+ exchanger only occurs in the distal
region of the cytosolic domain (8). Regulation of exchanger activity by
phosphorylation of the carboxyl-terminal domain (last 178 amino acids)
of the protein has been directly demonstrated using specific kinases
present in rabbit skeletal muscle (9) and rat vascular smooth muscle
cells (10). To date, however, no studies have examined regulation of
Na+/H+ exchanger activity by kinases isolated
from the myocardium. In this report, we identified two myocardial
kinases important in the regulation of the COOH-terminal domain of NHE1
MAP kinase and p90rsk or Rsk (a substrate for MAP kinase
phosphorylation). The results implicate a MAP kinase signaling pathway
in the regulation of the COOH-terminal domain of the NHE1 isoform of
the Na+/H+ exchanger and give the first direct
evidence of myocardial kinases involved in this regulation.
Materials--
PD98059, a MEK inhibitor, was from
Calbiochem-Novabiochem Corp. Plasmid pGEX-3X, glutathione-Sepharose 4B
affinity column, and protein A/G-Sepharose CL-4B beads were from
Amersham Pharmacia Biotech (Uppsala, Sweden). Anti-MAP kinase R2
(Erk1-CT) was from Kinetek Pharmaceuticals, Inc. (Vancouver, Canada),
while Anti-ERK-1 (rabbit polyclonal), anti-p-ERK (mouse monoclonal),
and anti-Rsk-1 (goat polyclonal) antibodies were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Anti-RSK (p90rsk) (mouse
monoclonal) was from Transduction Laboratories (Lexington, KY). MF-20
(mouse monoclonal) was purchased from the Developmental Studies
Hybridoma Bank (Iowa City, IA). [ Construction and Purification of Glutathione
S-Transferase-Na+/H+ Exchanger Fusion
Protein--
The carboxyl-terminal 178-amino acid sequence of the
rabbit cardiac Na+/H+ exchanger was expressed
as described previously (9) as a fusion protein with GST (PCRA or
PCR178) using the plasmid pGEX-3X (9). The Escherichia coli
TOPP 2 strain was induced with 1 mM
isopropylthio- Preparation and Fractionation of Cell Extracts from Adult Rat
Myocardium--
Extracts were prepared from ventricles of untreated
adult Harlan Sprague-Dawley rats. The heart tissue was homogenized at a
high setting with a Polytron homogenizer for 30 s in 2.5 (v/w) of
extraction buffer containing 10 mM sodium phosphate, 60 mM In Vitro Phosphorylation of the Na+/H+
Exchanger Fusion Protein (PCRA)--
The standard reaction conditions
for phosphorylation of heart extract fractions contained 3.0-8.0 µg
of PCRA, 8 µl of heart extract, 12.5 mM MOPS, pH 7.2, 0.5 mM EGTA, 2 mM dithiothreitol, 8.5 mM magnesium chloride, 6 µM okadaic acid,
0.24 mM sodium fluoride, 500 µM ATP, and 1 µl of 10 µCi/µl [ In-gel Kinase Assays--
To identify specific kinases that
phosphorylated PCRA, heart fractions of interest were separated by 10%
SDS-PAGE in a gel containing 1 mg/ml of PCRA. In-gel kinase assays were
as described earlier (9). The gel was dried for autoradiography and
visualization of phosphorylation (13).
Primary Cultures of Isolated Neonatal Myocytes--
Primary
myocyte cultures were prepared from neonatal Harlan Sprague-Dawley rats
as described previously (14). Isolated primary myocytes were plated
onto glass coverslips for physiologic studies or onto
PrimariaTM (Falcon) culture dishes or flasks. Myocytes were
maintained for 4-5 days in medium containing Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum (FBS), 10 µg/ml transferrin, 10 µg/ml insulin, 10 ng/ml selenium, 50 units/ml
penicillin, 50 µg/ml streptomycin, 2 mg/ml bovine serum albumin, 5 µg/ml linoleic acid, 3 mM pyruvic acid, 0.1 mM minimum essential medium nonessential amino acids, 10%
minimum essential medium vitamin, 0.1 mM bromodeoxyuridine, 100 µm L-ascorbic acid, and 30 mM HEPES, pH
7.1. Cells were serum-starved overnight prior to experiments when
myocytes were stimulated with serum or ET-1.
Measurement of Na+/H+ Exchanger
Activity--
Myocytes were grown on glass coverslips, and the acetoxy
methyl ester of 2'-7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein was
used to measure pHi as described earlier (9, 14, 15).
Excitation wavelengths were at 452 and 503 nm with emission at 524 nm.
Myocytes were serum-starved before pHi measurement, and the
normal buffer used for pH measurements contained 137 mM sodium chloride, 1.6 mM magnesium sulfate, 5.4 mM potassium chloride, 1.2 mM sodium dihydrogen
orthophosphate, 20 mM HEPES, 15 mM
D-glucose, and 1.0 mM calcium chloride, pH 7.1. Steady-state pHi was measured following a brief acid challenge
using ammonium chloride prepulse (20 mM for 2-3 min)
followed by ammonium chloride-free buffer pH 7.1 (14). After recovery
of a stable resting pHi, either serum (10%) or ET-1 (0.5 nM) was added, and changes in resting pHi were
measured for 10 min. In some experiments, the cells were either
pretreated with the MEK inhibitor PD98059 (50 µM) or
Me2SO vehicle for 2 min followed by the above stimulation with either serum or ET-1.
Endogenous Phosphorylation of NHE1 of Neonatal Cardiac
Myocytes--
To examine phosphorylation of NHE1 in vivo,
neonatal cardiac myocytes were incubated in a phosphate-free buffer
containing 130 mM sodium chloride, 5 mM
potassium chloride, 1.8 mM calcium chloride, 1.0 mM magnesium sulfate, 5.0 mM
D-glucose, 20.0 mM HEPES, 2.0 mM
glutamine, and 1.0 g/liter bovine serum albumin, pH 7.4, for 30 min at
37 °C (16, 17). Myocytes were then incubated with
[32P]orthophosphate (100 µCi/ml) for 3 h in
phosphate-free buffer at 37 °C. Five minutes before the incubation
was terminated, myocytes were stimulated with FBS (10%) for 5 min.
Unstimulated myocytes were used as controls. In some experiments,
myocytes were treated with PD98059 prior to immunoprecipitation as
described below. Cells were then washed with cold phosphate-free
buffer, and this was replaced with a cold buffer (RIPA) containing 150 mM sodium chloride, 80 mM sodium fluoride, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 1 mM EGTA, 25 mM tetrasodium pyrophosphate, 1 mM sodium orthovanadate (17) and placed on dry ice for
5-10 min. Myocytes were thawed on ice, scraped into centrifuge tubes,
sonicated for 10 s, and centrifuged at 35,000 rpm at 4 °C for
1 h. The supernatant was removed, and RIPA buffer containing 1%
(v/v) Nonidet P-40 (Nonidet P-40), 0.5% (w/v) deoxycholate, and 0.1%
(w/v) SDS was added. The solution was centrifuged at 10,000 rpm for 30 min at 4 °C, and the supernatant was frozen in liquid nitrogen and
kept at
Immunoprecipitations were with affinity-purified NHE1 antibodies
against the Na+/H+ exchanger (2). To reduce
nonspecific binding to Sepharose, radiolabeled myocyte extracts (1 ml)
were treated with protein A-Sepharose CL-4B beads for 30 min. These
samples were centrifuged for 1-2 min at 7000 rpm at 4 °C, and the
supernatant was retained. Sepharose beads used for immunoprecipitation
were also pretreated to reduce nonspecific binding. Unlabeled myocyte
extract was combined with protein A-Sepharose CL-4B beads for 2 h
at 4 °C, and the beads were washed with RIPA. For
immunoprecipitations, 30 µl of anti-NHE1 antibody (2) was added to
the pretreated supernatant, and this was agitated for 2 h at
4 °C. The antibody-antigen complex was then added to pretreated
beads and agitated for 1 h at 4 °C. The beads were washed
extensively with RIPA buffer and then solubilized in SDS-PAGE gel
sample buffer. The immunoprecipitate was boiled and run on a SDS-PAGE.
Finally, the gel was dried for autoradiographic analysis. In some
experiments, immunoprecipitates were transferred to Nitrocellulose and
probed with antibody against the antiporter to confirm their identity.
Immunoprecipitations were repeated three times in experiments comparing
FBS-stimulated and -unstimulated cells, and they were repeated two
times in experiments comparing PD98059-treated and -untreated cells. In
the experiments with PD98059, the amount of immunoprecipitate was
quantified by Western blotting and densitometric analysis to ensure
equivalent amounts of protein were compared.
Isolation of Cell Lysates Containing Activated MAP Kinase and
p90rsk from Neonatal Cardiac Myocytes--
To characterize
in vivo stimulated kinases, myocytes were serum-starved
overnight. To mimic conditions of the experiments measuring
pHi, myocytes were subjected to a brief ammonium chloride
prepulse as described above. Myocytes were then exposed to either 10%
FBS or 0.5 nM ET-1 for 0-5 min at 37 °C. Unstimulated myocytes were used as controls. In some experiments, the cells were
either pretreated with the MEK inhibitor PD98059 (50 µM) or Me2SO vehicle for 30 min followed by stimulation with
either serum or ET-1. The myocytes were washed with ice-cold
phosphate-buffered saline and an extraction buffer containing 50 mM tetrasodium pyrophosphate, 50 mM sodium
fluoride, 50 mM sodium chloride, 5 mM EDTA, 5 mM EGTA, 0.1 mM sodium orthovanadate, 0.01%
Triton X-100, 10 mM HEPES, pH 7.4, and a mixture of
protease inhibitors. The cells were frozen on dry ice for 5 min,
allowed to thaw on ice for 15 min, scraped, and transferred into
microcentrifuge tubes. The myocyte extracts were sonicated for 10 s on ice and then centrifuged at 10,000 rpm for 30 min at 4 °C.
Extracts were analyzed by Western blot analysis using antibodies
against MAP kinase (ERK-1), phosphorylated MAP kinase (p-ERK), cardiac
myosin heavy chain (MF-20), and p90rsk and for their ability to
phosphorylate PCRA fusion protein using the assays described earlier.
For in-gel kinase assays of stimulated and unstimulated neonatal
cardiac myocytes, cell lysates were made as described above. Equal
amounts of protein were then used for the in-gel kinase assays. We
confirmed that equal amounts of protein were applied to the gels by
Coomassie Blue staining of identically run gels or by Western blot
analysis of identically run samples with an antibody against either MAP
kinase or p90rsk. Protein concentrations were measured using
the Bio-Rad DC protein assay.
Immunoprecipitation of MAP Kinase and p90rsk from
Myocyte Extracts--
For immunoprecipitation, anti-ERK-1 and
anti-Rsk-1 antibodies were used. Myocyte lysates (500 µl) were
pretreated by incubating with protein A-Sepharose Cl-4B beads (in
experiments with anti-ERK-1 antibodies) or protein G-Sepharose beads
(in experiments with anti-Rsk-1) for 30 min. The samples were
centrifuged for 1-2 min at 7000 rpm at 4 °C to remove
nonspecifically adsorbed proteins bound to the resins. In addition,
Sepharose beads used for immunoprecipitation were pretreated to reduce
nonspecific binding. They were incubated with unlabeled myocyte extract
for 2 h at 4 °C and washed with extraction buffer. For
immunoprecipitation of protein kinases, 10 µl of 200 µg/ml stock
anti-ERK-1 antibody or 10 µl of 200 µg/ml stock anti-Rsk-1 antibody
was added to pretreated myocyte lysate, and this mixture was rotated
for 2 h at 4 °C. The antibody-antigen complex was then added to
pretreated beads and rotated for 1 h at 4 °C. The beads were
washed extensively in extraction buffer and then solubilized in
SDS-PAGE gel sample buffer. The immunoprecipitate was analyzed by
in-gel kinase assay.
Statistics--
Analysis of results was by a Mann-Whitney
U test and/or Student's unpaired t test on
direct numerical values obtained (18). Values presented are mean ± S.E. of the controls with the number of experiments indicated;
p values < 0.05 were considered statistically significant.
We produced the carboxyl-terminal 178 amino acids as a fusion
protein with GST (46.9 kDa). The identity of the purified protein was
confirmed using an antibody generated against the carboxyl-terminal region of the Na+/H+ exchanger (11) (not
shown). We used this protein to examine regulation of the
Na+/H+ exchanger by phosphorylation in the
mammalian myocardium. Initially, we isolated a cell extract from the
adult rat myocardium, and this extract was fractionated on a Mono Q
column. Both unfractionated and fractionated extract were tested for
their ability to phosphorylate PCRA-GST. Fig.
1 shows that unfractionated extract does
not phosphorylate purified GST protein (lane 1)
but does phosphorylate purified PCRA-GST fusion protein that contains
the terminal 178 amino acids of the Na+/H+
exchanger (46-47 kDa) (lane 2). The
stoichiometry of phosphorylation was 1-2 mol of Pi/mol of
PCRA-GST. A time course of phosphorylation showed that the fusion
protein was fully phosphorylated (not shown).
To examine which kinases might be involved in the phosphorylation of
the fusion protein, we analyzed the extracts by Western blot analysis
using commercially available antibodies against MAP kinase (ERK-1)
(Fig. 2A). Unfractionated
extract (CY) contained both MAP kinase (44 and 42 kDa)
isoforms as well as a small amount of the kinase p90rsk (90 kDa) when probed with an antibody to p90rsk (not shown).
Fractions 10-12 were enriched in MAP kinase relative to other
fractions, and these same fractions contained small amounts of
p90rsk protein (not shown).
Protein Kinase-mediated Regulation of the
Na+/H+ Exchanger in the Rat Myocardium by
Mitogen-activated Protein Kinase-dependent
Pathways*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP was
purchased from Amersham Pharmacia Biotech (Oakville, Canada), and
[32P]orthophosphate was obtained from ICN Radiochemicals
(Irvine, CA). Collagenase type 2 was obtained from Worthington, and
BCECF-AM was from Molecular Probes, Inc. (Eugene, OR).
-D-galactoside. PCRA was purified via
glutathione-Sepharose 4B affinity chromatography as described earlier
(9).
-glycerophosphate, 1 mM dithiothreitol,
15 mM EGTA, 15 mM magnesium chloride, pH 7.5, 10 mM phenylmethylsulfonyl fluoride in methanol, 1 mM benzamidine hydrochloride in ethanol, and a protease
inhibitor mixture (12). The homogenate was centrifuged at 6000 × g for 60 min at 4 °C. The supernatant was then
centrifuged at 10,000 × g for 60 min at 4 °C.
Muscle extracts were fractionated on a Mono Q 10 column using FPLC as
described previously (9). Western blot analysis was done using
commercially available antibodies against MAP kinase (ERK-1) and
p90rsk.
-32P]ATP (3000 Ci/mmol) in a
final volume of 24 µl (modified according to Ref. 9). Samples were
incubated at 30 °C for 90 min, and the reaction was terminated by
the addition of SDS loading buffer. Samples were run on a 12% SDS gel,
dried, and exposed for autoradiography. The stoichiometry of
phosphorylation was determined by two methods using samples separated
by SDS-PAGE. The appropriate bands were identified by autoradiography
and excised, and incorporation was measured by liquid scintillation
counting. The same results were obtained by quantification using a
model BAS1000 phosphor imager (Fuji Photo Film Co., Ltd.) to examine
radioactivity incorporated into the protein bands.
80 °C overnight.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 1.
Phosphorylation of
Na+/H+ exchanger fusion protein by
unfractionated cardiac muscle extracts. Samples were incubated in
buffer containing [
-32P]ATP, unfractionated cell
extracts, and fusion protein. The autoradiogram (lane
1) shows that purified GST protein is not phosphorylated by
cardiac muscle cell extracts, while PCRA-GST (lane
2) shows phosphorylation.

View larger version (41K):
[in a new window]
Fig. 2.
Identification of MAP kinase in adult rat
cardiac cell extracts. Western blot analysis was performed with
anti-MAP kinase R2 (rabbit polyclonal, 1:4000) antibodies against
fractionated cell extracts (lanes 8-15) and unfractionated
extract (lane CY). A, Western blot of
fractions 8-15 and unfractionated extracts with anti-MAP kinase
antibody (immunoreactive with 44- and 42-kDa isoforms). B,
in-gel kinase assay using PCRA-GST as a substrate (1 mg/ml);
unfractionated cardiac extracts and fractionated cardiac cell extracts
(lanes 8-14) are shown.
To identify potential protein kinases involved in regulation of the Na+/H+ exchanger, we used in-gel kinase assays. In-gel kinase assays with GST alone as a substrate showed no discrete phosphorylation patterns and no evidence that kinases were phosphorylating GST to any significant extent (not shown). However, assays with GST-PCRA as a substrate showed that a number of kinases of discreet molecular sizes could phosphorylate this fusion protein (Fig. 2B). In unfractionated samples (CY) the major kinase activity was of approximately 44 kDa. In addition, there was a minor band of approximately 38 kDa. Fractions 9-12 contained bands of kinase activity corresponding to molecular masses of approximately 44, 90, 60, and 38 kDa (Fig. 2B). A weak band was also noticed of approximately 75 kDa. The finding of kinases of about 44 and 90 kDa was consistent with the size and activity of MAP kinase and p90rsk. We did not find evidence for significant activity of protein kinases larger than 90 kDa.
We next characterized steady state physiological pHi regulation
by the Na+/H+ exchanger in isolated neonatal
myocytes stimulated with either ET-1 or FBS. Steady state monitoring of
pHi allowed us to observe a continuous time course of events.
Myocytes were serum-starved overnight. Fig.
3A shows typical effects of
the addition of ET-1 or FBS on steady-state pHi of neonatal
cardiac myocytes, and Fig. 3B summarizes the results. Both
ET-1 and FBS addition raised the steady-state pHi to more
alkaline values compared with unstimulated cardiac myocytes (control).
The MEK inhibitor PD98059 abolished the effects of ET-1 and FBS
addition, showing that the above effects were due to activation of the
Na+/H+ exchanger via the MAP kinase signal
transduction pathway. A summary of a series of experiments is shown in
Fig. 3B.
|
We then examined in vivo phosphorylation of NHE1 in neonatal
cardiac myocytes. Affinity-purified anti-Na+/H+
exchanger antibody was used to immunoprecipitate the exchanger from
equal amounts of isolated myocytes. Fig.
4B shows typical results and
illustrates that FBS stimulation increased the in vivo
phosphorylation state of the NHE1 compared with unstimulated myocytes.
Scanning densitometry estimated a 2-3-fold increase in the
phosphorylation level in stimulated cells. Fig. 4A shows a
typical Western blot of the immunoprecipitate probed with anti-NHE1 antibody. The result confirms that we were immunoprecipitating Na+/H+ exchanger protein. Fig. 4C
shows that PD98059 dramatically reduced the phosphorylation of the
antiporter that was induced by serum. Scanning densitometry estimated
that there was approximately a 5-fold decrease in the level of
phosphorylation.
|
To examine mechanisms behind the physiological effects, we obtained
cell extracts from neonatal cardiac myocytes that were unstimulated
(control) (Fig. 5A,
lane 1), ET-1-stimulated (lane 2), and FBS-stimulated (lane 3). All
of the extracts had the ability to phosphorylate PCRA-GST (46-47 kDa)
in in vitro phosphorylation assays. However, extracts from
ET-1 and FBS-stimulated cardiac myocytes showed a 2-fold increase in
phosphorylation of PCRA-GST (p < 0.05) compared with
controls (Fig. 5B).
|
To confirm that myocyte extracts contained equal amounts of protein and
kinases, SDS-PAGE and Western blot analysis routinely analyzed cell
lysates. Antibodies against MAP kinase (ERK-1) and p90rsk
showed that all of the extracts contained equal amounts of these two
kinases (Fig. 6A)
(lane 1, control extract; lane
2, extract from ET-1-stimulated myocytes; lane
3, extract from FBS-stimulated myocytes). Equal amounts of
protein were obtained from the different cells (0.8-1.0
µg/µl).
|
To confirm that the 44- and 90-kDa bands were MAP kinase and p90rsk, respectively, we used immunoprecipitation with anti-MAP kinase (44 kDa) and anti-p90rsk (90 kDa) antibodies. The proteins were removed from neonatal cardiac cell extracts with antibodies as described under "Experimental Procedures." The immunoprecipitates were tested for their ability to phosphorylate the carboxyl terminus of the Na+/H+ exchanger in an in-gel kinase assays (Fig. 6B). Lanes 1 and 3 show phosphorylation by the 42- and 44-kDa isoforms of MAP kinase and by p90rsk (Fig. 6B). Anti-MAP kinase antibody immunoprecipitated a band corresponding in size to the major 44-kDa kinase we found in cell extracts and was equivalent in size to that of MAP kinase (Fig. 6B, lane 2). Anti-p90rsk antibody immunoprecipitated a band that corresponded in size to p90rsk kinase and to the 90-kDa band we observed in whole cell and tissue extracts (Fig. 6B, lane 4). A control experiment in which no primary antibody was added did not show either a 42-44-kDa band or a 90-kDa band (not shown). Fig. 6C confirms that we immunoprecipitated the appropriate protein kinases. Lane 1 shows MAP kinase of a control cell extract, while lane 2 shows an extract in which much of the MAP kinase was removed by immunoprecipitation. Lane 3 shows immunoprecipitate of MAP kinase protein. The heavy and light chains of the IgG were also evident, but in control experiments they did not account for the MAP kinase band (not shown). Lane 4 shows p90rsk of a control cell extract, and lane 5 shows the extract after immunodepletion with anti-p90rsk antibody. Lane 6 shows that the immunoprecipitate contains p90rsk.
We performed time course experiments on the phosphorylation levels of
MAP kinase (Fig. 7A) and
p90rsk (Fig. 8, A and
B) and then used in-gel kinase assays to examine if MAP
kinase (Fig. 7B) and p90rsk (Fig.
9, A and B) respond
to the same physiological stimuli that affected pHi regulation.
Fig. 7A shows phosphorylation levels of MAP kinase in total
cell extracts detected with antibodies to the phosphorylated form of
MAP kinase (p-ERK). Control cells were unstimulated, while other cells
were FBS-stimulated for 30 s to 5 min. The same extracts were
probed with anti-MF-20 (antibody to cardiac myosin heavy chain) to show
equal amounts of protein loaded in each lane. Clearly, MAP kinase is
highly phosphorylated within 30 s of stimulation, and this
increases for up to 1 min in time. This is followed by a decrease in
the level of phosphorylation of MAP kinase. Fig. 7B shows an
in-gel kinase assay showing phosphorylation of PCRA by control
myocardial cell extracts (C) and cell extracts from 1-min,
FBS-stimulated myocytes (S) with and without the MEK inhibitor PD98059. The level of phosphorylation of PCRA-GST by MAP
kinase from FBS-stimulated myocyte extracts was much greater than
unstimulated (control) myocyte extracts (lane 1 versus lane 3). PD98059 reduced the
levels of MAP kinase phosphorylation of PCRA from both control myocyte
extracts and FBS-stimulated myocyte extracts (lanes
2 and 4).
|
|
|
In a second time course study, we examined the effects of 0, 2, and 5 min of ET-1 stimulation on phosphorylation of PCRA by p90rsk (Fig. 8A). The level of phosphorylation of PCRA by p90rsk increased significantly between the 2- and 5-min values (p < 0.05) (Fig. 8B). Thus, it appears that p90rsk is rapidly activated and phosphorylates the Na+/H+ exchanger after only 2 min of ET-1 stimulation. The activity increased even further with 5 min of stimulation.
To further characterize phosphorylation of the
Na+/H+ exchanger by p90rsk, we again
used the MEK inhibitor PD98059. Prior to stimulation with either ET-1
or FBS, isolated cardiac myocytes were subjected to 30 min of PD98059
treatment to inhibit MEK (as above). They were then treated with ET-1
or FBS. Fig. 9A is an in-gel kinase assay showing
non-PD98059-treated myocyte extracts from myocytes stimulated with FBS
(lanes 1 and 2) or ET-1
(lanes 3 and 4). PD98059 treatment
reduced p90rsk phosphorylation of PCRA-GST in extracts from
serum- and ET-1-stimulated myocytes (p < 0.05) (Fig.
9). As in previous experiments, extracts from unstimulated myocytes
showed only small amounts of phosphorylation, and this level was
reduced significantly (p < 0.05) with PD98059 treatment (not shown).
| |
DISCUSSION |
|---|
|
|
|---|
The Na+/H+ exchanger is an essential component of pH regulation in the mammalian myocardium. Regulation of the Na+/H+ exchanger has still not been well characterized at the molecular level, although it is clear that phosphorylation of the distal end of the cytoplasmic domain is important in activity in some cell types (8). We characterized extracts of intact hearts to determine which kinases could be involved in regulation of the antiporter in the myocardium. We used the carboxyl-terminal 178 amino acids of the Na+/H+ exchanger as a substrate for protein kinases, since phosphorylation of the antiporter has been shown to be restricted to this region (6). We separated myocardial extracts into fractions with different abilities to phosphorylate the antiporter. An early peak contained MAP kinase and p90rsk (Fig. 2A). A later peak did not contain significant amounts of these kinases according to Western blot analysis (not shown). It was clear that MAP kinase- and p90rsk-containing fractions were not the only ones capable of phosphorylating the antiporter. We characterized these fractions further using in-gel kinase assays. We found several different protein kinases that could phosphorylate the carboxyl terminus of the antiporter. In unfractionated cell lysate, the major kinase was 44 kDa (Fig. 2B). This was also a major band present in fractions 9-12. In addition, a 90-kDa band was present and some other kinases of varied sizes. We confirmed that the 44-kDa band and the 90-kDa band were due to MAP kinase and p90rsk, respectively, by immunoprecipitation of these proteins with their respective antibodies (Fig. 6B). It was interesting to note that both in the intact heart and in extracts from cardiac myocytes, several other protein kinases could phosphorylate the Na+/H+ exchanger COOH terminus. Two of these were 60 and 38 kDa and were present in fractions 9-13 of the intact heart extracts. The identities of the 60- and 38-kDa kinases are not known at this time.
Immunodetection with p90rsk antibodies was not nearly as strong as with anti-MAP kinase antibody. This was possibly due to low levels of kinase present in this tissue or due to an antibody of lower affinity. MAP kinase and p90rsk are known to exist together in a complex (19). Because we had identified p90rsk and MAP kinase as potential protein kinases that phosphorylate the antiporter and because we have previously shown an involvement of MAP kinase-dependent pathways in other tissues (9), we examined the role of MAP kinase-dependent pathways in the myocardium in more detail.
Endothelin has been shown earlier to augment activity of the Na+/H+ exchanger (21). Both serum and ET-1 elevated steady state pHi in isolated neonatal cardiac cells (Fig. 3). The MEK inhibitor PD98059 prevented the increases, suggesting that MAP kinase dependent pathways are involved. The increases in pHi occurred even up to 10 min after administration of the stimulation. We used an intermediate time of 5 min to examine the effect of this stimulation on protein kinase activity directed toward the Na+/H+ exchanger. The results showed that protein kinases were activated significantly with increased activity toward the carboxyl region of the antiporter (Fig. 5). It was also clear that this type of physiological stimulation can result in increased phosphorylation of the Na+/H+ exchanger in cardiac cells in vivo. Stimulation of isolated neonatal cardiac myocytes with serum resulted in increased phosphorylation of the endogenous Na+/H+ exchanger in intact cells, and this effect was blocked by PD98059. Clearly, protein kinase-mediated phosphorylation of the antiporter occurs in the intact myocardium. It was most interesting that PD98059 blocks the stimulatory effect of serum on activity of the antiporter (Fig. 3) and also blocks the stimulatory effects of serum on phosphorylation of the protein (Fig. 4C). This suggested that MAP kinase-dependent effects on phosphorylation of the antiporter in vivo correlated with effects on activity of the antiporter in intact cells.
We next examined which specific kinases were involved in phosphorylation that was stimulated by serum or ET-1. Stimulation with serum for 1 min increased the level of MAP kinase activity directed toward the Na+/H+ exchanger (Fig. 7), while stimulation with ET-1 for 2 min increased the level of p90rsk activity directed toward the Na+/H+ exchanger (Fig. 8). The MEK inhibitor PD98059 (Figs. 7 and 9) blocked this effect and also greatly reduced the basal level of phosphorylation by MAP kinase (Fig. 7) and p90rsk (not shown) toward the antiporter, suggesting that even in serum-deprived myocytes, a basal level of p90rsk and MAP kinase are involved in regulation of the antiporter.
The activity of p90rsk is dependent on activation by MAP kinase (22). Stimulation by serum and ET-1 probably lead to elevated MAP kinase activity that activates p90rsk (22). We found that MAP kinase is rapidly activated, and then its activity rapidly declines. The time course of activation of p90rsk was more consistent with the physiological effects we observed on activity (Fig. 3). However, it is possible that MAP kinase plays a direct role in early activation of the antiporter. The importance of the MAP kinase cascade in regulation of the antiporter has been demonstrated earlier (9, 23); however, the exact role of MAP kinase itself in regulation of the antiporter has been controversial. Earlier (9) we found an excellent time course of activation of MAP kinase activity toward the Na+/H+ exchanger and stimulation of Na+/H+ exchanger activity in smooth muscle cells. Similar to our earlier result (9), it was clear that MAP kinase could phosphorylate the antiporter directly in in-gel kinase assays. We also previously found that purified MAP kinase could phosphorylate the antiporter with a stoichiometry of 1 mol of phosphate/mol of protein. However, others were unable to demonstrate direct phosphorylation of the Na+/H+ exchanger using immunoprecipitated protein (23). It is known that under some conditions calmodulin (24), calcineurin homologous protein (25), and HSP70 (26) can all associate with the carboxyl terminus of the antiporter. It is possible that any of these proteins might obscure phosphorylation sites of immunoprecipitated protein. We have found that MAP kinase from three types of contractile cells (smooth muscle, skeletal (9) and cardiac cells) can directly phosphorylate the COOH terminus of the antiporter. In the present study, the results clearly showed that MAP kinase from cardiac cell extracts and from heart homogenates could phosphorylate the carboxyl terminus of the Na+/H+ exchanger. In in-gel kinase assays of cardiac myocytes, MAP kinase activity was the most prominent of all apparent protein kinases. The exact role and regulation of this direct phosphorylation by MAP kinase still needs further definition and may vary between cell types.
In the case of p90rsk, a regulatory role of direct phosphorylation of the Na+/H+ exchanger is more apparent. In the present study, we showed that there was an excellent correlation between activation of p90rsk activity toward the antiporter and increased activity of the Na+/H+ exchanger protein in vivo. This was the only protein kinase in the cell extracts that showed this clear correlation with antiporter activity. p90rsk is clearly a strong candidate for the protein kinase mediating the effects of ET-1 on the myocardial Na+/H+ exchanger. Supporting this suggestion is the observation (21) that blocking G-protein-mediated effects of endothelin does not block stimulation of the Na+/H+ exchanger. It was previously shown that p90rsk is important in regulation of the Na+/H+ exchanger in rat vascular smooth muscle (10). In addition, phosphorylation of the Na+/H+ exchanger by p90rsk was elevated in smooth muscle cells from spontaneously hypertensive rats, which may explain the increased activity of the antiporter seen in hypertensive patients (8). Our results support a direct regulatory role of p90rsk on the Na+/H+ exchanger in the cardiac myocyte. They are the first demonstration of phosphorylation of the Na+/H+ exchanger in the myocardium and of the particular kinases and receptors responsive to stimulation in the myocardium. Our results differ from those reported earlier (27) in that they again show a direct phosphorylation by MAP kinase, in support of our earlier findings (9). It was curious that the phosphorylation level of MAP kinase declined rapidly, while the activity of p90rsk continued to increase for up to 5 min. However, it is known that MAP kinase and p90rsk form a complex together (19) so that a small subfraction of activated MAP kinase could activate p90rsk. In addition, evidence has shown the p90rsk undergoes autophosphorylation coincident with kinase activation (29). Thus, it is possible that the further activation of p90rsk is the result of autophosphorylation by activated kinase.
Our results do not exclude the possibility that other protein kinases
may be involved in regulation of the Na+/H+
exchanger with different kinds of physiological stimuli. Several consensus sequences exist in the antiporter carboxyl terminus, and more
than 1 mol of phosphate is incorporated upon mitogenic stimulation of
some cell types (8). A recent report (30) suggests that
p160ROCK mediates phosphorylation of the antiporter by
lysophosphatidic acid, G
13, and RhoA. The kinase is involved in
actin stress fiber formation (30). A preliminary report suggests that
protein kinase D may act as a negative regulator of the antiporter
(28). We found no evidence for any significant activity of protein
kinases of larger apparent size than p90rsk. However, this does
not exclude a role for either of these kinases in the myocardium. It is
possible that the activity of other kinases is below the detection
level of this assay. It is also possible that p160ROCK and
protein kinase D may not function well in in-gel kinase assays that
require denaturation and renaturation of the kinases. In addition, in
the case of protein kinase D, there is no evidence for direct
phosphorylation of the exchanger. Its action may be through an
intermediate protein such as calcineurin homologous protein (25).
P160ROCK was shown to mediate direct phosphorylation of the
antiporter (30) and has been shown to be present in the myocardium
(20). However, it seems unlikely that it plays a role in the MAP kinase pathway stimulated by ET-1 and is more likely involved in control of
the cytoskeleton by RhoA. Further studies are necessary to examine if
this kinase has a role to play in the myocardium.
In summary, our results clearly show that MAP
kinase-dependent pathways are important mediators of
activation of the antiporter in the myocardium. The present study
supports the idea that p90rsk is an important kinase that may
be responsible for mediating the effects of ET-1 stimulation on
activity of the Na+/H+ exchanger. MAP kinase
was shown to phosphorylate the Na+/H+
exchanger, but its role in regulation is still unclear. We found that
other protein kinases of apparent molecular mass less than 80 kDa could
also phosphorylate the antiporter. Further experiments are necessary to
determine their identity and possible regulatory roles in the myocardium.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Marek Michalak for his laboratory's technical assistance in obtaining the FPLC samples used in this study.
| |
FOOTNOTES |
|---|
* This work was supported by a grant from the Heart and Stroke Foundation of Canada (to L. F.) and by a postdoctoral fellowship from the Alberta Heritage Foundation for Medical Research (to A. N. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
A Senior Scholar of the Alberta Heritage Foundation for Medical
Research. To whom correspondence should be addressed: Dept. of
Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada.
Tel.: 780-492-1848; Fax: 780-492-0886; E-mail: lfliegel@gpu.srv. ualberta.ca.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: NHE1, Na+/H+ exchanger isoform-1; ERK, extracellular signal regulated kinase; FPLC, fast performance liquid chromatography; GST, glutathione S-transferase; MAP, mitogen-activated protein; MEK, mitogen-activated protein kinase kinase; pHi, intracellular pH; MOPS, 4-morpholinepropanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; FBS, fetal bovine serum; RIPA, radioimmune precipitation buffer; ET, endothelin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Fliegel, L., and Dibrov, P. (1996) in The Na+/H+ Exchanger (Fliegel, L., ed) , pp. 1-20, Springer/R.G. Landes Co., Austin, TX |
| 2. | Haworth, R. S., Frohlich, O., and Fliegel, L. (1993) Biochem. J. 289, 637-640 |
| 3. |
Orlowski, J.,
and Grinstein, S.
(1997)
J. Biol. Chem.
272,
22373-22376 |
| 4. |
Numata, M.,
Petrecca, K.,
Lake, N.,
and Orlowski, J.
(1998)
J. Biol. Chem.
273,
6951-6959 |
| 5. | Orlowski, J., and Shull, G. (1996) in The Na+/H+ Exchanger (Fliegel, L., ed) , pp. 123-148, Springer/R.G. Landes Co., Austin, TX |
| 6. | Fliegel, L., and Wang, H. (1997) J. Mol. Cell Cardiol. 29, 1991-1999[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Karmazyn, M. (1996) in The Na+/H+ Exchanger (Fliegel, L., ed) , pp. 189-216, Springer/R.G. Landes Co., Austin, TX |
| 8. |
Wakabayashi, S.,
Bertrand, B.,
Shigekawa, M.,
Fafournoux, P.,
and Pouyssegur, J.
(1994)
J. Biol. Chem.
269,
5583-5588 |
| 9. | Wang, H., Silva, N. L. C. L., Lucchesi, P. A., Haworth, R., Wang, K., Michalak, M., Pelech, S., and Fliegel, L. (1997) Biochemistry 36, 9151-9158[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Takahashi, E.,
Abe, J.,
and Berk, B. C.
(1997)
Circ. Res.
81,
268-273 |
| 11. | Besson, P., Fernandez-Rachubinski, F., Yang, W., and Fliegel, L. (1998) Am. J. Physiol. 274, C831-C839 |
| 12. |
Michalak, M.,
Fliegel, L.,
and Wlasichuk, K.
(1990)
J. Biol. Chem.
265,
5869-5874 |
| 13. |
Lucchesi, P. A.,
Bell, J. M.,
Willis, L. S.,
Byron, K. L.,
Corson, M. A.,
and Berk, B. C.
(1996)
Circ. Res.
78,
962-970 |
| 14. | Dyck, J. R. B., Maddaford, T. G., Pierce, G. N., and Fliegel, L. (1995) Cardiovasc. Res. 29, 203-208[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Chaillte, J. R.,
and Boron, W. F.
(1985)
J. Gen. Physiol.
86,
765-795 |
| 16. | Moe, O. W., Amemiya, M., and Yamaji, Y. (1995) J. Clin. Invest. 96, 2187-2194 |
| 17. |
Siczkowski, M.,
Davies, J. E.,
and Ng, L. L.
(1995)
Circ. Res.
76,
825-831 |
| 18. | Hassard, T. H. (1991) in Understanding Biostatistics (Hassard, T. H., ed) , pp. 263-280, Mosby Year Book, Inc., St. Louis, MO |
| 19. |
Hsiao, K. M.,
Chou, S. Y.,
Shih, S. J.,
and Ferrell, J. E., Jr.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5480-5487 |
| 20. | Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K., and Narumiya, S. (1996) 392, 189-193 |
| 21. |
Kramer, B. K.,
Smith, T. W.,
and Kelly, R. A.
(1991)
Circ. Res.
68,
269-279 |
| 22. |
Davis, R. J.
(1993)
J. Biol. Chem.
268,
14553-14556 |
| 23. |
Bianchini, L.,
L'Allemain, G.,
and Pouyssegur, J.
(1997)
J. Biol. Chem.
272,
271-279 |
| 24. | Wakabayashi, S., Ikeda, T., Iwamoto, T., Pouyssegur, J., and Shigekawa, M. (1997) Biochemistry 36, 12854-12861[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Lin, X., and Barber, D. L. (1996) J. Biol. Chem. 93, 12631-12636 |
| 26. | Silva, N. L. C. L., Haworth, R. S., Singh, D., and Fliegel, L. (1995) Biochemistry 34, 10412-10420[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Phan, V. N., Kusuhara, M., Lucchesi, P. A., and Berk, B. C. (1997) Circ. Res. 29, 1265-1272 |
| 28. | Haworth, R., Rozengurt, E., and Avkiran, M. (1998) J. Mol. Cell. Cardiol. 30, 337[CrossRef][Medline] [Order article via Infotrieve] (abstr.) |
| 29. |
Bjorbaek, C.,
Zhao, Y.,
and Moller, D. E.
(1995)
J. Biol. Chem.
270,
18848-18852 |
| 30. | Tominaga, T., Ishizaki, T., Narumiya, S., and Barber, D. L. (1998) EMBO J. 17, 4712-4722[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
I. Szokodi, R. Kerkela, A.-M. Kubin, B. Sarman, S. Pikkarainen, A. Konyi, I. G. Horvath, L. Papp, M. Toth, R. Skoumal, et al. Functionally Opposing Roles of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase in the Regulation of Cardiac Contractility Circulation, October 14, 2008; 118(16): 1651 - 1658. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Grenier, K. Abu-ihweij, G. Zhang, S. M. Ruppert, R. Boohaker, E. R. Slepkov, K. Pridemore, J.-J. Ren, L. Fliegel, and A. R. Khaled Apoptosis-induced alkalinization by the Na+/H+ exchanger isoform 1 is mediated through phosphorylation of amino acids Ser726 and Ser729 Am J Physiol Cell Physiol, October 1, 2008; 295(4): C883 - C896. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Moncoq, G. Kemp, X. Li, L. Fliegel, and H. S. Young Dimeric Structure of Human Na+/H+ Exchanger Isoform 1 Overproduced in Saccharomyces cerevisiae J. Biol. Chem., February 15, 2008; 283(7): 4145 - 4154. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Iwata, Y. Katanosaka, T. Hisamitsu, and S. Wakabayashi Enhanced Na+/H+ Exchange Activity Contributes to the Pathogenesis of Muscular Dystrophy via Involvement of P2 Receptors Am. J. Pathol., November 1, 2007; 171(5): 1576 - 1587. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Luo, D. B. Kintner, G. E. Shull, and D. Sun ERK1/2-p90RSK-mediated Phosphorylation of Na+/H+ Exchanger Isoform 1: A ROLE IN ISCHEMIC NEURONAL DEATH J. Biol. Chem., September 21, 2007; 282(38): 28274 - 28284. [Abstract] [Full Text] [PDF] |
||||
![]() |